Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

121.08 +1.91 (+1.60%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Glaukos Announces FDA Approval of Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Expert Outlook: Glaukos Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Expert Outlook: Glaukos Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos (GKOS) Q2 Revenue Jumps 30% ↗
Via The Motley Fool
News headline image
Glaukos Announces Second Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
What 11 Analyst Ratings Have To Say About Glaukos ↗
 
Via Benzinga
News headline image
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Glaukos Announces First Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Forecasting The Future: 7 Analyst Projections For Glaukos ↗
 
Via Benzinga
News headline image
Glaukos Announces the Release of its 2024 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
From Glaukos Corporation
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
From Glaukos Corporation
Via Business Wire
News headline image
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery ↗
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential. 
Via Benzinga
News headline image
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
News headline image
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition ↗
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.